Cefiderocol’s In Vitro Activity Against Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter: Insights for Research and Resistance Modeling

Study Background and Research Question

The global rise in antimicrobial resistance, particularly among non-fermenting Gram-negative pathogens such as Pseudomonas aeruginosa and Acinetobacter species, poses a significant threat to clinical treatment options. Carbapenem-resistant strains, which have become notably prevalent in Europe, leave clinicians with a narrowing arsenal of effective antibiotics. In response to this challenge, Henriksen and colleagues conducted a large multicenter investigation to evaluate the in vitro activity of cefiderocol—a novel siderophore cephalosporin—against European clinical isolates of P. aeruginosa and Acinetobacter, including those resistant to both carbapenems (e.g., meropenem) and the latest β-lactam/β-lactamase inhibitor combinations. The central research question addressed whether cefiderocol offers a meaningful therapeutic advantage in the context of evolving resistance patterns, especially for isolates where standard therapies are ineffective (see reference study).

Key Innovation from the Reference Study

The study represents the first direct, large-scale comparison of cefiderocol and recent β-lactam/β-lactamase inhibitor combinations—including ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, and imipenem-relebactam—against a comprehensive collection of non-fermenting Gram-negative isolates from hospitalized European patients. Notably, the work incorporates a robust molecular characterization of resistance mechanisms, leveraging both PCR and whole-genome sequencing to identify prevalent β-lactamase genes and mutations associated with cefiderocol resistance. This integrated approach sets a new standard for resistance surveillance and informs rational antibiotic selection in highly resistant infections.

Methods and Experimental Design Insights

The investigators assembled 1,451 clinical isolates (950 P. aeruginosa and 501 Acinetobacter spp.) from 49 sites across six European countries during a single year. Susceptibility testing covered cefiderocol and a suite of modern β-lactam/β-lactamase inhibitor combinations. Isolates exhibiting resistance to meropenem (MIC >8 mg/L) or cefiderocol underwent further molecular analysis:

• PCR was used to detect major β-lactamase genes among meropenem-resistant isolates, focusing on metallo-β-lactamases (e.g., blaVIM-2) in P. aeruginosa and oxacillinases (e.g., blaOXA-23) in Acinetobacter spp.
• Whole-genome sequencing was performed on cefiderocol-resistant isolates to uncover acquired resistance genes and key mutations (notably, pirA/piuA).
• Susceptibility rates were compared using EUCAST and CLSI breakpoints, ensuring clinical relevance.

By defining meropenem resistance according to the high-dose MIC breakpoint, the design mirrors real-world clinical scenarios where resistance would impact therapeutic choices (reference study).

Core Findings and Why They Matter

Several results stand out for their implications in both clinical and research contexts:

• Cefiderocol demonstrated superior in vitro activity compared to all tested β-lactam/β-lactamase inhibitor combinations. Among P. aeruginosa isolates, 98.9% were susceptible to cefiderocol, markedly higher than the 83.3%–91.4% seen with other combinations.
• Activity against highly resistant strains: In meropenem-resistant P. aeruginosa (n = 139), cefiderocol susceptibility remained at 97.8%, compared to only 12.2%–59.7% with other regimens. For isolates resistant to both meropenem and ceftazidime-avibactam or ceftolozane-tazobactam, cefiderocol activity persisted at >96%—a critical finding for multidrug-resistant infections.
• Acinetobacter spp. findings: Cefiderocol and sulbactam-durlobactam both showed high susceptibility rates (92.4% and 97.0%, respectively). However, efficacy against sulbactam-durlobactam- or cefiderocol-resistant strains was limited (13.3% and 65.8%, respectively).
• Genetic mechanisms: The majority of meropenem-resistant P. aeruginosa carried metallo-β-lactamases (notably blaVIM-2), while meropenem-resistant Acinetobacter spp. predominantly harbored blaOXA-23. Cefiderocol resistance was associated with acquired β-lactamase genes and specific pirA/piuA mutations.

These results confirm that cefiderocol retains exceptionally high activity against non-fermenters, including those with complex resistance patterns that undermine most available β-lactams. The findings support its role as a critical agent when facing infections due to multidrug-resistant P. aeruginosa and Acinetobacter (reference study).

Comparison with Existing Internal Articles

Several internal resources contextualize these results within broader resistance research and experimental design:

• The article "Aztreonam: Monocyclic β-Lactam Antibiotic in Resistance Research" discusses the use of monocyclic β-lactam antibiotics like Aztreonam for targeted inhibition of Gram-negative aerobic bacteria, as well as workflow optimization for resistance profiling. While Aztreonam’s spectrum overlaps with cefiderocol, the latter’s activity against metallo-β-lactamase producers highlights the need for parallel susceptibility testing, as emphasized by the reference study.
• "Aztreonam: Monocyclic β-Lactam Solutions for Resistance Research" further explores how synthetic β-lactam antibiotics can support advanced modeling of resistance mechanisms, aligning with the reference study’s recommendation for early, comprehensive susceptibility testing of both established and newer agents.
• For mechanistic insights, "Aztreonam in Translational Research: Mechanistic Precision" details Aztreonam’s inhibition of bacterial cell wall synthesis and its effects on mammalian systems, offering complementary experimental angles for resistance and toxicity screening.

Collectively, these resources underscore the importance of integrating monocyclic β-lactam antibiotics—such as Aztreonam—into research workflows, particularly for resistance modeling and susceptibility testing alongside cefiderocol.

Protocol Parameters

• Non-fermenter isolate collection: Source clinical isolates from respiratory tract and other infection sites to mirror epidemiological distributions.
• Susceptibility testing: Use broth microdilution or agar dilution according to EUCAST/CLSI guidelines for cefiderocol and comparator antibiotics.
• Molecular resistance profiling: Apply PCR for β-lactamase gene detection and whole-genome sequencing for in-depth analysis of resistant strains.
• Aztreonam handling: For in vitro testing, prepare Aztreonam at ≥10 mM in DMSO or ≥10.24 mg/mL in water using ultrasonic assistance, as indicated by the product information. Store solid Aztreonam at -20°C for maximal stability; use solutions promptly.
• Parallel susceptibility workflows: Run susceptibility panels for cefiderocol, Aztreonam, and other β-lactams in parallel to capture resistance phenotypes informed by local epidemiology.

Limitations and Transferability

The reference study’s main strength lies in its extensive geographic and isolate coverage; however, several limitations merit attention:

• In vitro design: Antimicrobial activities were measured in vitro and may not fully translate to clinical outcomes, particularly in the context of biofilm formation or altered pharmacokinetics in patients.
• Genetic diversity: The study’s molecular analyses focused on established resistance genes and known mutations; rare or emerging mechanisms may be underrepresented.
• Geographic scope: Isolates were exclusively European; resistance patterns elsewhere may differ, affecting transferability.

Despite these limitations, the structured approach to resistance mechanism identification and the alignment with clinical resistance definitions provide valuable guidance for both research and translational applications.

Why this cross-domain matters, maturity, and limitations

The intersection of microbiology, molecular genetics, and clinical pharmacology in this study demonstrates the maturity of integrated surveillance approaches for antimicrobial resistance. By combining susceptibility testing with genetic profiling, researchers can more accurately model resistance evolution and inform the selection of both established and novel agents. Limitations remain regarding the extrapolation of in vitro efficacy to patient outcomes and the need for further clinical validation in diverse populations.

Research Support Resources

For researchers aiming to replicate or extend resistance modeling workflows, Aztreonam (SKU A5931) is available as a fully synthetic monocyclic β-lactam antibiotic with targeted activity against Gram-negative aerobic bacteria. Its well-characterized inhibition of bacterial cell wall synthesis and established use in both microbiological and mammalian metabolism studies make it a practical tool for resistance profiling and susceptibility testing. For optimal application, follow recommended solubility and storage protocols, and consider parallel testing with agents such as cefiderocol to capture a comprehensive resistance landscape. Aztreonam is supplied by APExBIO for research use only.